couter

ETONEton Pharmaceuticals, Inc.

Health CarePharmaceuticals

The Read

Historically, Eton Pharmaceuticals' merger and M&A-related events have triggered median stock moves of about 11%.
Oct 20, 2026 — DESMODA (ET-600) Commercial Launch Metrics Update
Chart by TradingView

The schedule

  • Tue20Oct

    A dedicated product update on the DESMODA rollout to pressure-test the market's aggressive peak sales assumptions.

  • Sun20Dec

    Decision on the New Drug Application (NDA) for ET-600, a proprietary oral liquid desmopressin formulation for diabetes insipidus, addressing a significant unmet pediatric need.

  • Fri5Feb

    Q3 results combining updated commercial run-rates with the expected formal initiation of ET-700's Phase III trials.

  • Tue9Feb

    Full-year 2026 recap and the all-important initial 2027 top-line guidance issued under President Trump's regulatory FDA framework.

  • Mon10May

    Q1 2027 results will serve as an operational scorecard for ETON's expanding pediatric commercial footprint and cash flow generation.

Past

  • Wed30Sep

    Top-line clinical results for the ET-700 PET study, serving as a critical pipeline catalyst outside the established commercial portfolio.

  • Sun9Aug

    Q2 earnings will reveal whether Hemangeol integration and DESMODA launch metrics can sustain the stock's 100% run to its 52-week high of $38.02.

  • Thu25Jun

    Actual outcome: Bull · $38.02 at outcome

    Eton Pharmaceuticals avoided announcing a dilutive secondary offering during the catalyst window, alleviating investor concerns about immediate shareholder dilution. With the financing overhang removed, the market focused on the company's underlying commercialization progress and M&A pipeline, driving shares up 9.2% to easily surpass the $32.50 bull target.

    Market anticipation of a potential dilutive capital raise to fund commercialization efforts and M&A pipeline after the recent share price appreciation.

  • Thu14May

    Actual outcome: Bull · $32.49 at outcome

    Eton Pharmaceuticals reported record Q1 2026 product sales of $24.3 million, representing 73% year-over-year growth, and raised its full-year revenue guidance to over $120 million. Although GAAP EPS of $0.05 missed some analyst estimates, the robust top-line performance and positive early launch progress for DESMODA and HEMANGEOL drove the stock's 8.4% rally toward the bull target.

    ETON reports Q1 2026 earnings from its current $30.38 apex, setting the baseline for the DESMODA commercial launch. Strong early adoption metrics target $33.00, while cautious guidance yields a $26.50 fallback.

  • Thu19Mar

    Actual outcome: Mixed · $19.02 at outcome

    Eton Pharmaceuticals reported Q4 2025 earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share, despite improving from a loss of $0.02 a year ago. This bottom-line shortfall disappointed investors, driving an 8.4% decline in the stock price following the announcement.

    Reporting full year 2025 results with a focus on margin recovery following heavy investment cycles.